Recent developments highlight Seer’s ongoing commercialization efforts, financial reporting, collaborations, and insider transactions.

• Seer, Inc. announced it will report second quarter 2025 financial results on August 6, 2025 [N1].
• A director sold 30,253 shares of Seer stock in an insider transaction reported in June 2025 [N2].
• Seer and Korea University launched a large-scale study to identify early-onset cancer biomarkers using the Proteograph ONE Assay [N3].
• Seer reported quarterly earnings and strong first quarter 2025 financial results with $4.2 million in revenue [N5][N6].
• Seer announced plans to report first quarter 2025 financial results on May 13, 2025 [N7].
• The company showcased innovations in proteomics at the US HUPO 2025 Annual Conference in February 2025 [N8].
• Additional insider sales were reported, including the President & CFO selling 3,550 shares in February 2025 [N2].
• Seer’s stock experienced a 13% increase on May 14, 2025, with data analysis provided [N4].

Seer’s integrated proteomics platform addresses a growing market for proteome analysis tools, with early revenue generation and collaborations indicating initial market traction. The company’s strong liquidity supports ongoing commercialization and product development efforts. Its proprietary nanoparticle technology and software complement the hardware instruments, potentially offering a differentiated solution. Collaborations with academic institutions and key opinion leaders may facilitate scientific acceptance and adoption. Expansion of sales and marketing capabilities could enhance market penetration and revenue growth.

Seer is an early-stage company with a history of significant net losses and limited operating history, which increases uncertainty about its future viability. The commercialization of the Proteograph Product Suite faces risks including slow or limited market adoption, manufacturing and supply chain challenges, and competition from larger, better-resourced companies. The company’s revenues are concentrated among a few customers, and failure to diversify could adversely impact financial results. Regulatory compliance and quality control risks may also affect operations. Additional capital may be required, which could dilute existing shareholders or impose operational constraints.

Seer’s moat is based on its integrated Proteograph Product Suite combining hardware, consumables, proprietary engineered nanoparticle technology, and software, which together provide a comprehensive proteomics solution. The complexity and quality requirements of the instruments, along with proprietary technology and ongoing collaborations with academic institutions, create barriers to entry. However, the company faces competition from large, established life sciences companies with broader product lines, greater resources, and established customer bases, as well as from emerging proteomics technology firms. Maintaining scientific and market acceptance is critical to sustaining its competitive position.

• Early-stage company with limited operating history: Seer has a limited operating history and has incurred significant net losses, which may continue, making it difficult to evaluate future viability and performance.
• Market acceptance and commercialization risks: The success of the Proteograph Product Suite depends on broad scientific and market acceptance, which may be slow or limited, affecting revenue and growth.
• Manufacturing and supply chain risks: Complex manufacturing processes and reliance on third-party suppliers and contract manufacturers may lead to delays, quality defects, or supply interruptions.
• Competition: Seer faces competition from large, established life sciences companies and emerging proteomics firms with greater resources and broader product lines.
• Customer concentration: Revenues are concentrated among a small number of customers, including related parties, which could materially affect financial results if lost or reduced.
• Regulatory and compliance risks: The company must comply with various regulations including data privacy, export controls, and labeling laws, with potential adverse effects if not met.
• Financial risks and capital requirements: Seer may need to raise additional capital to fund commercialization and development, which could dilute shareholders or impose operational restrictions.

• Seer, Inc. is a life sciences technology company focused on developing and commercializing the Proteograph Product Suite, an integrated proteomics solution.
• The company is in early stages of commercialization and has a limited operating history, having been formed in 2017.
• Seer has incurred significant net losses historically and as of September 30, 2025, had an accumulated deficit of approximately $450 million.
• The company generated $4.2 million in revenue in the first quarter of 2025.
• Seer’s business depends on sales to commercial companies, academic institutions, and research organizations, with some concentration in a few customers including PrognomiQ.
• The Proteograph Product Suite includes hardware (SP100 and SP200 automation instruments), consumables, proprietary engineered nanoparticle technology, and software (Proteograph Analysis Suite).
• Manufacturing of instruments is performed by Hamilton Company under complex and quality-controlled processes.
• Seer faces competition from large life sciences companies such as Agilent Technologies, Bio-Techne, Bruker, Danaher, DiaSorin, Thermo Fisher Scientific, and emerging proteomics companies.
• The company’s sales and marketing capabilities are limited but expanding, with efforts to build a specialized sales force and distributor network.
• Seer has a strong cash position with $47.3 million in cash and equivalents as of December 31, 2025, and a current ratio of 12.84, indicating strong liquidity.
• Net income for the fiscal year ended December 31, 2025, was a loss of $73.6 million.
• The company’s board of directors includes experienced members with backgrounds in biotechnology, life sciences, and finance.
• Seer collaborates with academic institutions such as Korea University on large-scale studies using its Proteograph ONE Assay.
• The company’s products are labeled for research use only and are not intended for clinical diagnostic use.
• Seer’s commercialization success depends on broad scientific and market acceptance of the Proteograph Product Suite, which is subject to adoption risks.
• The company faces risks related to manufacturing complexity, supply chain dependencies, and potential quality defects in its integrated product suite.
• Seer’s operating results may fluctuate significantly due to factors including sales cycles, customer adoption, pricing, and external market conditions.
• The company may require additional capital to fund commercialization, research and development, and expansion activities.
• Seer’s business is subject to regulatory compliance risks, including data privacy laws and export regulations.
• The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.